author-photo

Hans Loibner

University of Graz

160

Papers

3400

Citations

Citation Trend

Filter By

Papers (110) Sort By

Journal Conference Others

Ralph A. Reisfeld, PhD: In Memoriam (1926–2020)

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

2020 Cancers
Show All
- Source
- Cite
- Save
Citations (29)
Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front–line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
Low regulatory T-cells are associated with improved survival of neuroblastoma patients treated with anti-GD2 antibodies

2019
Show All
- Source
- Cite
- Save
Citations (0)
Abstract A013: Haploidentical stem cell transplantation and subsequent immunotherapy with antiGD2 antibody for patients with relapsed metastatic neuroblastoma

2019 Cancer immunology research
Show All
- Source
- Cite
- Save
Citations (3)
Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2

2019 OncoImmunology
Show All
- Source
- Cite
- Save
Citations (7)
Immunotherapy with anti-GD2 antibody ch14.18/CHO±IL2 within the HR-NBL1/SIOPEN trial to improve outcome of high-risk neuroblastoma patients compared to historical controls.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (8)
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

2018 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (121)
Survival of neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor (KIR) genotypes and Fcγ-receptor polymorphisms.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial

2018 Cancers
Show All
- Source
- Cite
- Save
Citations (7)